| Name | Title | Contact Details |
|---|
Deciphera Pharmaceuticals is inspired to improve treatment for patients with cancer by designing kinase inhibitor therapies that target the hallmarks of cancer biology. Our small-molecule drugs are specifically engineered to simultaneously block multiple cancer signaling mechanisms in the tumor cell and the tumor microenvironment to prevent growth and spread. Deciphera’s unique approach represents an important advance over current therapies in the durability of kinase inhibition and resiliency to genetic mutations to provide greater benefit across a range of cancers. Deciphera’s business strategy is to advance its drug candidates for genetically-defined cancers and cancers that target the tumor microenvironment through both proprietary and partnered programs. Deciphera’s internal product pipeline includes Altiratinib (DCC-2701) a MET/TIE2/VEGFR2/TRK kinase inhibitor currently in Phase 1 clinical development, DCC-2618, a pan-KIT inhibitor currently in preclinical development and Rebastinib, a TIE2/VEGFR1 kinase inhibitor currently in Phase 1 clinical development. Partnered programs include LY3009120 (DP-4978), a pan-RAF inhibitor developed in collaboration with Eli Lilly. Additional research-stage programs are also in development.
Kinect is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Deltanoid Pharmaceuticals, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Concord is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Worldwide Clinical Research is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.